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A B S T R A C T
Background
Epilepsy is a highly prevalent neurological condition characterized by repeated unprovoked seizures with various etiologies. Although
antiepileptic medications produce clinical improvement in most individuals, nearly a third of individuals have drug-resistant epilepsy
that carries significant morbidity and mortality. There remains a need for non-invasive and more effective therapies for this population.
Transcranial magnetic stimulation (TMS) uses electromagnetic coils to excite or inhibit neurons, with repetitive pulses at low-frequency
producing an inhibitory effect that could conceivably reduce cortical excitability associated with epilepsy.
Objectives
To assess the evidence for the use of TMS in individuals with drug-resistant epilepsy compared with other available treatments in
reducing seizure frequency, improving quality of life, reducing epileptiform discharges, antiepileptic medication use, and side-effects.
Search methods
We searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) via
the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 10 March 2016), ClinicalTrials.gov and the World
Health Organization International Clinical Trials Registry Platform (ICTRP) up to March 2016. We also searched SCOPUS (1823 to
June 2014) as a substitute for Embase (but it is no longer necessary to search SCOPUS, because randomized controlled trials (RCTs)
and quasi-RCTs in EMBASE are now included in CENTRAL).
Selection criteria
Eligible studies were RCTs that were double-blinded, single-blinded or unblinded, and placebo, no treatment, or active controlled,
which used repetitive transcranial magnetic stimulation (rTMS) without restriction of frequency, duration, intensity, or setup (focal
or vertex treatment) on patients with drug-resistant epilepsy. The search revealed 274 records from the databases, that after selection
provided seven full-text relevant studies for inclusion. Of the seven studies included, five were completed studies with published data
and included randomized, blinded trials. The total number of participants in the seven trials was 230.
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Data collection and analysis
We extracted information from each trial including methodological data; participant demographics including baseline seizure frequency,
type of epileptic drugs taken; intervention details and intervention groups for comparison; potential biases; and outcomes and time
points, primarily change in seizure frequency or responder rates, as well as quality of life and epileptiform discharges, adverse effects,
and changes in medication use.
Main results
Two of the seven studies analyzed showed a statistically significant reduction in seizure rate from baseline (72% and 78.9% reduction
of seizures per week from the baseline rate, respectively). The other five studies showed no statistically significant difference in seizure
frequency following rTMS treatment compared with controls. We were not able to combine the results of the trials in analysis due
to differences in the designs of the studies. Four studies evaluated our secondary endpoint of mean number of epileptic discharges,
and three of the four showed a statistically significant reduction in discharges. Quality of life was not assessed in any of the studies.
Adverse effects were uncommon among the studies and typically involved headache, dizziness, and tinnitus. No significant changes in
medication use were found in the trials.
Authors’ conclusions
Overall, we judged the quality of evidence for the primary outcomes of this review to be low. There is evidence that rTMS is safe and
not associated with any adverse events, but given the variability in technique and outcome reporting that prevented meta-analysis, the
evidence for efficacy of rTMS for seizure reduction is still lacking despite reasonable evidence that it is effective at reducing epileptiform
discharges.
P L A I N L A N G U A G E S U M M A R Y
Transcranial magnetic stimulation for treatment of epilepsy
Background
Epilepsy is a common neurological disorder that appears in various forms. Many individuals with epilepsy have satisfactory seizure
control with the use of antiepileptic medications. Yet, nearly a third of individuals suffer from frequent and uncontrolled seizures despite
taking medications, or find that they cannot tolerate the side-effects of those medications. Surgery is an option for some individuals
with uncontrolled seizures, but it is invasive and not suitable for all individuals. Therefore, there remains a substantial unmet need for
safe, effective therapies for these harder-to-treat epilepsies.
Transcranial magnetic stimulation (TMS) is one of several emerging treatments that can potentially offer individuals a safe and non-
invasive alternative to epilepsy surgery. Long used as a research tool to study brain function, TMS has also been studied as a possible
treatment for a number of neurological conditions, including epilepsy. This non-surgical and painless treatment uses induced magnetic
currents to modulate brain function in order to reduce the tendency to have seizures.
Objective
This review aims to assess the evidence for the use of TMS in individuals with epilepsy compared with other available treatments
in reducing seizure frequency, improving quality of life, reducing epileptiform discharges (sharp or spiking abnormalities on brain
electrographic testing that suggest underlying brain disturbance or seizure tendency that can be focal, multifocal, or diffuse), antiepileptic
medication use, and side-effects.
Methods
The last search for trials for this review was 10 March 2016. We assessed the evidence from seven randomized controlled trials (230
participants) comparing TMS to control treatments (’sham’ (placebo)) TMS, antiepileptic medication, and low-frequency TMS). We
were not able to combine the results of the trials in analysis due to differences in the designs of the studies; therefore, we have summarized
the results of the seven studies narratively.
Results
Some of the trials show that TMS reduces the number of seizures individuals had compared to before the therapy, but other trials did
not show any significant differences in seizure frequency. Four trials showed a reduction in epileptiform discharges following TMS
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treatment. None of the studies measured changes in quality of life, and only one trial reported an increase in antiepileptic medication
in a single person. Side-effects were not commonly reported; the most frequent side-effect reported was headache (and the majority of
individuals completed the treatment with TMS).
Quality of the evidence
Overall, we judged the quality of the evidence in this review for the main outcome of reduction in seizure frequency to be low due
to unclear information in the published papers about how the studies were designed and unclear presentation of results. This review
provides no information about the effect of TMS on quality of life. It is important that future studies are larger and measure important
outcomes, such as the effect of TMS on reducing seizure frequency, improving quality of life, and any side-effects associated with TMS
compared with other available treatments.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Repetitive transcranial magnetic stimulation (rTM S) compared with control for epilepsy
Patient or population: adults and children with epilepsy
Settings: outpat ients
Intervention: repet it ive transcranial magnetic st imulat ion (rTMS)
Comparison: control treatment (see footnote 1)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)2
No. of Participants
(studies)
Quality of the evidence
(GRADE)2
Comments
Assumed risk Corresponding risk
Control treatment1 Repetitive transcranial
magnetic stimulation
(rTM S)
Reduct ion in seizure
f requency: the propor-
t ion of people with
a 50% or greater re-
duct ion in seizure f re-
quency following the
treatment period
See comment See comment Not est imable 99 (3 studies) ⊕⊕©©
low3,4
In one study (Fregni
2006), there was a sta-
t ist ically signif icant ad-
vantage to rTMS com-
pared with sham rTMS,
and in the two other
studies no stat ist ically
signif icant dif f erence
was found between
rTMS and sham rTMS
(Cantello 2007) or non-
focal rTMS (Joo 2007)
Reduct ion in seizure
f requency: the dif fer-
ence in pre- and post-
treatment seizure rates
See comment See comment Not est imable 215 (7 studies) ⊕⊕©©
low3,5
Three studies reported
stat ist ically signif icant
reduct ions in seizure
rates post-treatment in
the rTMS group (
Fregni 2006; Sun 2012;
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Tergau 2003), while
four studies did not
f ind a stat ist ically sig-
nif icant reduct ion in
seizure f requency in
the rTMS group (
Cantello 2007; Joo
2007; Theodore 2002;
Wang 2008) Between-
group dif ferences were
not reported
Improvement in qual-
ity of lif e: the dif fer-
ence in quality of lif e
scores for part icipants
surveyed before and af -
ter treatment
Not reported Not reported Not est imable NA NA Quality of lif e was not
reported in any of the
included studies
* The basis for the assumed risk and the corresponding risk are the narrat ive summaries of the studies contribut ing to each outcome. A relative effect is not est imable as
meta-analysis was not performed2
CI: Conf idence interval; NA: not available
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Control treatments were sham rTMS (placebo), ant iepilept ic drug treatment, low-intensity rTMS (compared with high-intensity
rTMS) and non-focal rTMS (compared with focal rTMS).
2Due to variat ion in study design, intervent ions, and outcomes measured in the seven studies, we deemed meta-analysis to
not be appropriate and we discussed the seven studies narrat ively in the review. The GRADE judgement for each outcome is
based on the characterist ics and narrat ive results of the studies which contribute to each outcome.
3Downgraded due to unclear design and methodological information in the included studies (unclear risk of bias).
4Downgraded due to imprecision; small number of part icipants contribute to the outcome.
5Presentat ion of results did not allow for comparisons between rTMS and control, only within rTMS group were pre- and post-
treatment seizure rates available.
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B A C K G R O U N D
Description of the condition
Epilepsy is a highly prevalent neurological disorder affecting an es-
timated 70 million people worldwide (Ngugi 2010). There are 50
new cases per 100,000 people globally each year and up to 82 new
cases per 100,000 people in developing countries (Ngugi 2011).
One of the world’s oldest recognized conditions, epilepsy affects
all age groups and has various presentations and causes. Epilepsy
is characterized by repeated unprovoked seizures (episodes of con-
tinual discharges of brain activity) and can be considered a conse-
quence of an underlying condition, such as a tumour, or of genetic
alterations, brain malformations, infection, intoxication, or an-
other illness (Shorvon 2011). Although antiepileptic medications
produce clinical improvement, enabling most individuals to con-
trol their seizures, a 2008 study conducted in France estimated that
22.5% of individuals have ’drug-resistant’ epilepsy (Picot 2008),
leading to increased risks of premature death, injury, psychosocial
dysfunction, and a reduced quality of life (Kwan 2011). Individ-
uals whose epilepsy is resistant to medication may pursue alterna-
tive therapies including surgery, high-fat, low-carbohydrate diets,
and vagus nerve stimulation. Although these other therapies can
be quite effective, they have limitations in that the diets have poor
adherence and the procedural treatments are invasive and effective
only in selected populations. Therefore, there remains a need for
non-invasive and more effective therapies.
Description of the intervention
Transcranial magnetic stimulation (TMS) was developed in 1985
in the UK to study and map different areas of brain activity
(Kimiskidis 2010). In the study of epilepsy, TMS has been used to
probe cortical excitability in various epilepsy syndromes, to assess
the effects of antiepileptic drugs on the brain, and to help iden-
tify areas of the brain more prone to seizure for surgical removal
(Kimiskidis 2010). Once it became known that repeated pulses
of TMS could either excite or suppress neural activity for a pro-
longed period of time, TMS was studied as a potential therapy
for a number of neurological and psychiatric conditions, ranging
from stroke to depression to amyotrophic lateral sclerosis (Ridding
2007). Recently, studies have looked at TMS as a potential treat-
ment for epilepsy (Kimiskidis 2010). TMS is a procedure that uses
magnetic fields to stimulate nerve cells in the brain to improve the
symptoms of epilepsy. With TMS, a large electromagnetic coil is
placed against the scalp. The electromagnet creates electrical cur-
rents that stimulate nerve cells in the region of the brain involved
in epilepsy.
How the intervention might work
The prolonged inhibitory effects of TMS are thought to reduce
cortical hyperexcitability associated with various epilepsies. Al-
though the exact mechanisms remain a topic of active investiga-
tion, emerging evidence suggests TMS can generate either exci-
tatory or inhibitory responses in cortical tissue. A TMS device
employs either one or two copper coils, positioned superficial to a
site of interest in the brain, to non-invasively produce a brief (100
to 400 µs) magnetic pulse (generating a 1.5 to 2 T magnetic field)
to an estimated depth of ~2 cm. This magnetic pulse induces an
electrical current in a patch of cortical tissue of a few square cen-
timetres, causing a depolarisation of nearby axons (Reithler 2011).
Such local stimulation can even affect distant areas in ways that are
poorly understood (Reithler 2011). It has beenobserved that repet-
itive pulses of TMS can cause long-lasting effects, persisting for
more than one hour after a treatment (Huang 2005). Aside from
physical positioning of the device, there is no known way to target
particular cell types and various interactions between excitatory
and inhibitory processes may occur. However, repetition at higher
frequencies generally has an overall excitatory effect while, con-
versely, low-frequency repetitive pulses have an inhibitory effect
on neurons and may suppress the activity related to seizures. Ear-
lier animal studies showed that a single TMS pulse follows a par-
ticular time course, producing an initial facilitation or excitation
followed by delayed and prolonged suppression (Moliadze 2003).
Thus, low-frequency repetitive stimulation has been hypothesized
to result in prolonged synaptic depression when each incoming
pulse arrives during the late inhibitory phase produced by the pre-
vious pulse, however this has not been not proven (Reithler 2011).
Other important parameters in the use of TMS include intensity
and duration.
Why it is important to do this review
Repetitive transcranial magnetic stimulation (rTMS) is an emerg-
ing therapy for epilepsy, a highly prevalent neurological condition
for which a significant proportion of individuals do not achieve
an adequate response to medications. Drug-resistant epilepsy is
associated with reduced quality of life and such individuals often
face surgery or other invasive therapies, which carry significant
risks. Even individuals responsive to pharmacological therapy may
struggle with the possible adverse effects of their medications. In
contrast, rTMS is a painless, non-invasive approach that, if ef-
fective, could have significant advantages over both antiepileptic
drugs and surgical management. This systematic review will clarify
the available scientific evidence to help clinicians and individuals
assess the safety and effectiveness of this approach for the treat-
ment of epilepsy.
O B J E C T I V E S
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To assess the evidence for the use of TMS in individuals with
drug-resistant epilepsy compared with other available treatments
in reducing seizure frequency, improving quality of life, reducing
epileptiform discharges, antiepileptic medication use and side-ef-
fects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Eligible studies included:
1. randomized controlled trials (RCTs);
2. double, single or unblinded;
3. placebo/sham-controlled, no treatment or active controlled
(e.g. antiepileptic drug treatment).
Types of participants
Any participant of any age, with any type of drug-resistant epilepsy
syndrome, which includes unclassified types of epilepsy and post-
surgical epilepsy participants.
Types of interventions
Repetitive transcranial magnetic stimulation of any frequency, ei-
ther single or double-coiled, for any duration and at any intensity
added to current therapy or used as single therapy.
Types of outcome measures
Primary outcomes
Reduction in seizure frequency
• The proportion of people with a 50% or greater reduction
in seizure frequency following the treatment period.
• The difference in pre- and post-treatment seizure rates.
Improvement in quality of life
• The difference in quality of life scores for participants
surveyed before and after treatment.
Secondary outcomes
Reduction in epileptiform discharges
Mean number of epileptiform discharges seen on electroen-
cephalography (EEG) during the period between seizures.
Adverse effects
The proportion of people experiencing any of the following ad-
verse effects that are considered to be common and important po-
tential adverse effects of transcranial magnetic stimulation.
• Behavioral changes
• Cognitive disturbances
• Headache
• Tinnitus
• Pain/discomfort
• Sedation
• Seizures
The proportion of people experiencing the six most common ad-
verse effects, if different from the list above.
Changes in medication requirements
• The proportion of people who required fewer seizure
medications after treatment.
• The proportion of people who required more seizure
medications after treatment.
• The proportion of people who had no changes to their
medication after treatment.
Treatment withdrawal
• The proportion of people withdrawn from the study for
any reason.
• The proportion of people withdrawn from the study due to
lack of efficacy or adverse effects.
Search methods for identification of studies
Electronic searches
We searched the following databases.
• Cochrane Epilepsy Group Specialized Register (searched 10
March 2016), using the search strategy outlined in Appendix 1.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 2) via the Cochrane Register of Studies
Online (CRSO; searched 10 March 2016), using the search
strategy outlined in Appendix 2.
• MEDLINE Ovid (1946 to 10 March 2016), using the
search strategy outlined in Appendix 3.
7Transcranial magnetic stimulation for the treatment of epilepsy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch; searched 10 March
2016), using the following search strategy: transcranial magnetic
stimulation AND epilepsy NOT NCT*.
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 10 March
2016), using the following search strategy: ’transcranial magnetic
stimulation’ AND epilepsy.
In addition, we searched SCOPUS (1823 to 1 June 2014) as a sub-
stitute for Embase, using the search strategy outlined in Appendix
4, but it is no longer necessary to search SCOPUS, because RCTs
and quasi-RCTs in Embase are now included in CENTRAL.
We did not impose any date or language restrictions.
Searching other resources
We checked the reference lists of retrieved reports for additional
reports of relevant studies. We contacted the authors of any con-
ference proceedings to identify any unpublished data and experts
in the field to identify any further ongoing trials.
Data collection and analysis
Selection of studies
Two review authors (RC and DS) independently assessed articles
for inclusion. Any disagreements were resolved though mutual
discussion; failing this, advice from a third party (JW or SN) was
sought and a consensus determination was made.
Data extraction and management
We extracted the following information from each trial using a
data extraction sheet.
Methodological/trial design
1. Method of randomisation and allocation concealment.
2. Method of blinding.
3. Number of people excluded from reported analyses.
4. Duration of baseline period.
5. Duration of treatment period.
Individual participant/demographic information
1. Total number of participants allocated to each treatment
group.
2. Age/gender.
3. Number of participants within each epilepsy type.
4. Seizure frequency during baseline period.
5. Type of background antiepileptic drugs taken.
Intervention
1. Total number of intervention groups and comparisons.
2. Intervention details.
3. Potential biases.
Outcomes
1. Outcomes and time points reported.
2. Definition of outcome.
3. Unit of measurement.
Assessment of risk of bias in included studies
Two review authors (RC and DS) independently assessed the risk
of bias for each trial using the Cochrane ’Risk of bias’ tool as
described in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). We discussed any disagreements and
reached a consensus. If an agreement could not be made, a third
party opinion (JW or SN) was sought. We rated included studies
as high, low or unclear risk of bias on six domains of bias applica-
ble to RCTs: method of randomisation, method of concealing al-
location, method of blinding, incomplete outcome data, selective
outcome reporting, and other sources of bias.
Measures of treatment effect
We intended to present an overall effect estimate for seizure re-
duction as a risk ratio. We intended to present an overall effect
estimate for the difference in pre- and post-treatment seizure rates
and the reduction in the number of epileptiform discharges seen
on EEG during the period between seizures as a mean difference.
We intended to present overall effect estimates for adverse effects,
changes in medication requirements, and withdrawals as risk ra-
tios. We intended to present an overall estimate for the difference
in quality of life scores before and after treatment as mean dif-
ference (or standardized mean difference if varying quality of life
scales were used across studies).
Unit of analysis issues
Seizure reduction may be reported using different measures in
trials. In this event, we sought data from study authors in order to
obtain data suitable to be combined in meta-analysis. The unit of
analysis in all included studies was the individual.
If future updates of this review include studieswith units of analysis
other than the individual (e.g. cluster-randomized studies), wewill
implement themethods described inChapter 16.4 of theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We included two cross-over studies in the review. We would have
liked tohave analysed the results of these studies via paired analyses,
taking account of the correlated structure of the treatment groups
(Elbourne 2002), however insufficient data were presented in the
publications for such an analysis and we have narratively presented
the results of the studies.
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Dealing with missing data
We sought missing data from study authors. We intended to carry
out intention-to-treat, best-case, and worst-case analyses in order
to account for any missing data (see Data synthesis for details).
We intended to present all analyses in the main report.
Assessment of heterogeneity
We intended to assess clinical heterogeneity by comparing im-
portant participant and intervention factors among trials includ-
ing: age, seizure type, duration of epilepsy, number and type of
antiepileptic drugs taken at time of randomisation, study meth-
ods, loss to follow-up, and missing data. We intended to examine
statistical heterogeneity using a Chi2 test for heterogeneity and the
I2 statistic. Providing no significant heterogeneity is present (P >
0.1), we intended to employ a fixed-effect meta-analysis. In the
event heterogeneity is found to be present, we intended to carry
out a random-effects analysis and present both results in the main
report.
Assessment of reporting biases
We assessed the included studies for reporting biases using the
Cochrane ’Risk of bias’ tool. In the event outcome reporting bias
was suspected, we investigated this using the ORBIT classification
system (Kirkham 2010). We requested all protocols from study
authors to enable a comparison between a list of a priori listed
outcomes and what was reported in the matching papers. We in-
tended to examine publication bias via asymmetry of funnel plots
if ten or more trials had been combined. However, as insufficient
studies were included in the review, we made an informal assess-
ment by identifying certain aspects of each study, including spon-
sors of the research and research teams involved.
Data synthesis
We were not able to performmeta-analysis of the included studies
in this review due to variation in study design, interventions, and
outcomes measured.
However, for future updates of the review, if further studies are
included and meta-analysis is possible, we intend to employ a
fixed-effect meta-analysis to synthesise data, or in the case that
substantial heterogeneity is present, a random-effects method (see
Assessment of heterogeneity). Comparisons we expect to carry out
include:
1. intervention group versus control on seizure reduction;
2. intervention group versus control on reduction in
epileptiform discharges;
3. intervention group versus control on adverse effects;
4. intervention group versus control on treatment withdrawal.
We will stratify each comparison by type of control group (e.g.
placebo, other active treatment, no treatment) to enable appropri-
ate combination of study data.
Our preferred effect estimate is a risk ratio. For all outcomes,
except adverse effects, we will use 95% confidence intervals. For
individual adverse effects we will use 99% confidence intervals to
make allowance for multiple testing.
All analyses will include all participants in the treatment group
to which they were allocated. For the efficacy outcome of seizure
reduction we intend to employ three analyses as follows.
1. Primary (intention-to-treat) analysis: participants not
completing follow-up or with inadequate seizure data were
assumed non-responders. To test the effect of this assumption,
we employed the following sensitivity analyses.
2. Worst-case analysis: participants not completing follow-up
or with inadequate seizure data were assumed non-responders in
the magnetic stimulation group, and responders in the control
group.
3. Best-case analysis: participants not completing follow-up or
with inadequate seizure data were assumed responders in the
magnetic stimulation group and non-responders in the control
group.
’Summary of findings’ and quality of the evidence
(GRADE)
In a post-hoc change from the protocol, we have added a ’Summary
of findings’ table to the review (Summary of findings for the
main comparison), reporting the primary outcomes of the review
(reduction in seizure frequency and quality of life).
We determined the quality of evidence using the GRADE con-
siderations of study limitations, consistency of effect, imprecision,
indirectness, and publication bias (Atkins 2004).
We downgraded evidence by one level if we considered the limi-
tation serious and two levels if considered very serious. Under the
GRADE approach, evidence may also be upgraded if a large treat-
ment effect is demonstrated with no obvious biases or if a dose-
response effect exists.
Subgroup analysis and investigation of heterogeneity
If further studies are included in the update of this review and
meta-analysis is possible, we intend to carry out subgroup analysis
of any variable trial and participant characteristics (e.g. cross-over
compared to parallel trial design, adults compared to children,
epilepsy types etc.) to explore heterogeneity, if this is found.
Sensitivity analysis
If further studies are included in the update of this review and
meta-analysis is possible, we intend to carry out sensitivity analysis
if deemed appropriate, including the sensitivity analysis described
in Data synthesis to account for the presence of missing data. If
peculiarities were found between studies with regards to quality,
characteristics of participants, interventions and/or outcomes, we
would conduct a sensitivity analysis to explore these differences.
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R E S U L T S
Description of studies
Results of the search
The search revealed 274 records from the databases outlined in
Electronic searches. After we removed duplicates (92), we screened
the remaining 182 records for eligibility. We excluded 173 studies
at this point due to irrelevance and one study was an ongoing study
(NCT01745952). This left eight full-text articles to be assessed,
of which we included seven in the review (Cantello 2007; Fregni
2006; Joo 2007; Sun 2012; Tergau 2003; Theodore 2002; Wang
2008), and excluded one due to study design (NCT00382707);
see Included studies and Excluded studies for further information.
Due to variation in study design, interventions, and outcomes
measured in the seven studies, we deemed meta-analysis to not
be appropriate and we have discussed the seven studies narratively
within the review, see Figure 1 for further information.
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Figure 1. Study flow diagram.
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Included studies
We included seven randomized controlled trials (RCTs) that com-
pared repetitive transcranial magnetic stimulation (rTMS) with
active or placebo controls (Cantello 2007; Fregni 2006; Joo 2007;
Sun 2012; Tergau 2003; Theodore 2002; Wang 2008). Three
studies were placebo controlled (Cantello 2007; Fregni 2006;
Theodore 2002), one study compared transcranial magnetic stim-
ulation (TMS) of different intensities (Sun 2012), one study com-
pared TMS of different intensities with placebo (Tergau 2003),
one study compared focal to non-focal application of TMS (Joo
2007), and one study compared TMS with antiepileptic drug
treatment (Wang 2008).
All recruited participants had drug-resistant epilepsy of varying
definitions across studies; generally defined as at least one complex
partial or secondarily generalized seizure per month (but most
required 3 or more seizures per week) and an unchanging drug
regimenof at least two antiepilepticmedications. All used standard
figure-8 coils to deliver rTMS, although sham methods differed.
Cantello 2007 presented an Italian multi-center, cross-over trial
that was a randomized, double-blind, sham-controlled trial, with a
pre-treatment period of 12weeks, five days of active treatment, and
a follow-up evaluation period of six weeks. Forty-three participants
were randomized to either active first or placebo first treatment
with six weeks of follow-up after each treatment phase (active or
sham). Active rTMS was administered twice daily for five days
using two circular coils of 500 stimuli at 0.3Hz, separated by a 30-
second interval at an intensity of 100% of resting motor threshold
(RMT).
Fregni 2006 published a randomized, double-blind, sham-con-
trolled trial in Brazil with a baseline period of four weeks, five
days of active treatment, and a post-treatment evaluation period of
eight weeks. Twenty-one participants were randomized to active (n
= 12) and sham (n = 9) treatment arms. For the treatment group,
the participants received either focal rTMS, based on the known
location of abnormalities on their electroencephalography (EEG),
or at midline (CZ site) if there were diffuse EEG abnormalities.
They were administered rTMS for 20 minutes a day for five days
at settings of 1 Hz, 1200 pulses, at 70% of RMT intensity.
Joo 2007 presented results from their Korean study, which was a
randomized, double-blind, but not placebo controlled study. They
used a baseline surveillance period of eight weeks, five days of
active treatment, and a post-treatment evaluation period of eight
weeks. Thirty-five subjects with focal, non-focal, or multifocal
epilepsy were randomized into one of four subgroups (F-1500,
F-3000, NF-1500, NF-3000) to either receive focal or non-focal
rTMS for five days, delivering a total of either 1500 (50 minutes)
or 3000 pulses (100 minutes) a day, at an intensity of 100% of
RMT, 0.5 Hz frequency. The participants were assessed with daily
symptom logs before the treatment period and at eight weeks post-
stimulation.
Sun 2012 presented a Chinese randomized, single-blind, non-
placebo controlled study with a baseline evaluation period of four
weeks, two weeks of active treatment and eight weeks of clinical
follow-up. Sixty participants were randomized to one of two treat-
ment arms: high-intensity rTMS at 90% of RMT (n = 31) and
low-intensity rTMS at 20% RMT (n = 29). rTMS was delivered
three times a day for two weeks to the focal epileptic zone best
reflected on EEG with 500 stimuli at 0.5 Hz, separated by a 600-
second interval.
Tergau 2003 presented an interim analysis of a randomized, multi-
center, cross-over study conducted over three centers in Germany
with three treatment arms; placebo stimulation, 0.333 Hz stim-
ulation and 1 Hz stimulation. Baseline period was three months,
treatment periods were five days followed by a four week observa-
tion period. All three treatment periods were separated by at least
eight weeks. Treatment was delivered unifocally for all three arms,
with 1000 pulses each day (500 monopolar pulses with clockwise
current direction followed directly by 500 pulses in anticlockwise
direction). Data were available for 17 participants in the interim
analysis who had received all three treatments.
Theodore 2002 published a randomized, double-blind, placebo
controlled trial conducted at the National Institutes of Health,
with a baseline evaluation of eight weeks, one week of active treat-
ment, and a post-treatment follow-up period of eight weeks. Their
study randomized 24 participants with localization-related drug-
resistant epilepsy into active (n = 12) and placebo (n = 12) treat-
ment arms. rTMS was administered at an intensity of 120% RMT
at 1 HZ frequency, for 15 minutes, twice a day, for one week.
Wang 2008 presented a randomized, open-label, antiepileptic drug
controlled trial at a single center in China. Fifteen participants
were randomized to 1 Hz TMS at 90% RMT threshold, simu-
lation frequency of 500 times, once a day for seven days and 15
participants were randomized to 600 mg to 800 mg oral carba-
mazepine per day for at least 60 days. Outcomes were measured
30 days after treatment with TMS.
Excluded studies
We only excluded one study from the review after full-text evalu-
ation (NCT00382707). This was due to the study design, as the
trial was a controlled before-and-after study, and not a RCT.
Risk of bias in included studies
Two review authors (RC and DS) independently made an assess-
ment of the risk of bias for each trial using the Cochrane ’Risk
of bias’ tool as described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). Any disagreements were
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discussed and resolved by consensus or discussion with a third re-
view author (JW or SN). We assessed six domains for each trial:
allocation concealment, randomization method, blinding, com-
pleteness of data, selective outcome reporting, and other bias. No-
table risks of bias are highlighted as follows. We considered Wang
2008, a randomized but open-label study, to be at high risk of
detection bias, as outcome assessors were not blinded. We deemed
Tergau 2003, an interim analysis, to be at high risk for attrition
bias due to incomplete outcome data and unclear risk of perfor-
mance bias, since blinding was not described. We found Joo 2007
to have a high risk of reporting bias as no primary or secondary
outcomes were defined in their methods section. The majority of
studies showed unclear risk of selection bias when the allocation
concealment method was not specified.More detailed findings for
each study are summarized below in the ’Risk of bias’ tables and
in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Two studies described adequate methods of generating random se-
quences (computer-assisted generation of random sequence) and
we judged them to be at low risk of bias (Cantello 2007; Sun
2012). Three studies described that studies were ’randomized’ but
no information was provided on methods of generating random
sequences (Tergau 2003; Theodore 2002; Wang 2008), and one
study reported that a “randomization code” was used but with no
details of how the code was generated (Joo 2007).We judged these
four studies to be at unclear risk of bias. One study stated that
the ’order of entrance’ into the trial was used as well as computer-
generated randomization blocks (Fregni 2006). It is unclear ex-
actly how the ’order of entrance’ was taken into account in the
randomization and whether this could have led to a predictable
randomisation sequence, and so we judged this study to be at un-
clear risk of selection bias.
None of the studies reported how allocation was concealed and so
we judged all seven studies to be at unclear risk of bias.
Blinding
Five of the seven studies were described as “double-blind” (
Cantello 2007; Fregni 2006; Joo 2007; Sun 2012; Theodore
2002). In four of the five studies, only the investigator(s) responsi-
ble for initiating rTMS treatment were not blinded; participants,
all other personnel and outcome assessors were blinded and so we
judged these four studies to be at low risk of performance and
detection bias (Cantello 2007; Fregni 2006; Sun 2012; Theodore
2002). In the other study (Joo 2007), only blinding of the EEG
reader was described; it was unclear if participants and other per-
sonnel and outcome assessors were blinded and so we judged this
study to be at unclear risk of performance and detection bias.
In Tergau 2003, blinding of interventions was not mentioned,
even though a ’placebo stimulation’ was used; we judged this study
to be at unclear risk of performance and detection bias.
Wang 2008 randomized participants to TMS or drug treatment
and so blinding or participants and personnel would not be pos-
sible by design; it is unclear how this design may have influenced
outcomes and so we judged this study to be at unclear risk of per-
formance bias. Blinding of outcome assessors in a trial of this de-
sign would be possible, however it appears that outcome assessors
were not blinded and so we judged this study to be at high risk of
detection bias.
Incomplete outcome data
In five studies there were no apparent missing data, study attrition
was reported (if any withdrawals occurred from the study), and an
intention-to-treat (ITT) approach to analysis was used and so we
judged these five studies to be at low risk of attrition bias (Cantello
2007; Fregni 2006; Sun 2012; Theodore 2002; Wang 2008).
In one study there were no apparent missing data and no with-
drawals from treatment reported, but ITT analysis is not specified
and so we judged this study to be at unclear risk of attrition bias
(Joo 2007).
InTergau 2003, an interim analysis is presented for 17 participants
out of 28 randomized (5 participants were yet to complete the
study and 6 had dropped out). An ITT approach was not used
to analysis and it was unclear when participants dropped out and
how many of the cross-over arms had been completed. We judged
this study to be at high risk of attrition bias.
Selective reporting
Study protocols were not available for any of the included studies
and so we made a judgement regarding selective reporting bias
based on study publications alone. In five studies, all primary and
secondary outcomes stated in the methods section were reported
in the results and all expected outcomes were reported and so we
judged these studies to be at low risk of reporting bias (Cantello
2007; Fregni 2006; Sun 2012; Theodore 2002; Wang 2008).
In two studies (Joo 2007; Tergau 2003), no primary or secondary
outcomes were specified in the methods section and so we judged
that the results of these studies were at high risk of selective re-
porting bias.
Other potential sources of bias
In five studies, we did not identify any other sources of bias and
so we judged these studies to be at low risk of bias (Fregni 2006;
Joo 2007; Sun 2012; Theodore 2002; Wang 2008).
In the two included cross-over studies (Cantello 2007; Tergau
2003), the carryover effect was not formally assessed but the obser-
vation period of six weeks and eight weeks, respectively, between
treatments is likely to be a sufficient “washout period”. However, it
was not stated in either of these studies howmanyparticipantswere
randomized to each treatment arm first and whether these ran-
domized groups were balanced for clinical demographics at base-
line. Furthermore, for Tergau 2003, it is unclear how a three-arm
cross-over trial design was to be implemented and so we judged
these studies to be at unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Repetitive
transcranial magnetic stimulation (rTMS) compared with control
for epilepsy
Due to variation in study design, interventions, and outcomes
measured in the seven studies, we deemed meta-analysis to not be
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appropriate and we discussed the seven studies narratively within
the review. See Summary of findings for the main comparison for
a summary of the quality of evidence for the primary outcomes of
the review.
Primary outcomes
Reduction in seizure frequency
The proportion of people with a 50% or greater reduction in
seizure frequency following the treatment period
Three studies reported on this primary outcome. Only Fregni
2006 reported a statistically significant and high responder rate of
10 out of 12 participants in their intervention arm experiencing
> 50% reduction in seizures (including 3 participants who were
seizure-free) comparedwith zero responders in the shamprocedure
group. The proportion of responders was not statistically different
between the intervention and sham arms in Cantello 2007. For
example, four weeks after treatment, 9/43 and 3/43 participants
in the active and sham procedure groups, respectively, exhibited a
50% reduction of seizures, but this was not a statistically signifi-
cant difference. Joo 2007 also reported no statistically significant
difference in responder rates, but compared only focal versus non-
focal use of TMS without a placebo control. The other four stud-
ies did not report on this outcome.
The difference in pre- and post-treatment seizure rates
All seven of the studies reported on this primary outcome, how-
ever generally within-treatment group results were reported rather
than comparisons between treatment groups. Fregni 2006 showed
a statistically significant reduction of seizure frequency by 72% of
baseline after two weeks of treatment that continued (53% at 4
weeks, 58% at 8 weeks) in the active treated group. There was no
significant change in seizure frequency in the sham treated group.
Sun 2012 also reported a statistically significant 78.9% reduction
of seizure frequency from baseline (8.9 to 1.8 seizures per week)
in the high-intensity treatment group. There was no significant
change in frequency after treatment in the low-intensity treat-
ment group. The study did not have a placebo control group. In
Theodore 2002, there was no significant reduction in seizure fre-
quency in either the active or placebo groups, although a trend was
reported. The study by Tergau 2003 showed no significant reduc-
tion of seizure frequency in the two intervention groups (0.333Hz
and 1.0 Hz) compared with placebo overall. However, there was
a statistically significant, approximately 40% reduction in seizure
frequency two weeks following intervention when compared with
baseline. This difference was not significant when compared with
placebo. Similarly, Joo 2007, Cantello 2007, and Wang 2008 re-
ported no significant reduction in seizure frequency in either treat-
ment group.
Improvement in quality of life
The difference in quality of life scores for participants
surveyed before and after treatment
None of the studies reported on this primary outcome.
Secondary outcomes
Reduction in epileptiform discharges
Mean number of epileptiform discharges seen on
electroencephalography (EEG) during the period between
seizures
Four of the studies reported on this secondary outcome. Fregni
2006 reported a statistically significant reduction of epileptiform
discharges in the active treatment group of 31% immediately af-
ter the five-day treatment and 16% at four weeks prior to wash-
ing out. There was no significant change in number of epilepti-
form discharges in the sham group. Sun 2012 reported a signifi-
cant reduction of epileptiform discharges to 65.8% in the first 24
hours in the high-intensity treatment group, whereas the number
of epileptiformdischarges did not change frombaseline in the low-
intensity treatment group. In Cantello 2007, the mean reduction
in number of epileptiform discharges was not statistically signif-
icant. In Joo 2007, epileptiform discharges were significantly re-
duced by 54.9% after rTMS treatment in all groups combined. In
Theodore 2002, Wang 2008, and Tergau 2003, the mean num-
ber of epileptiform discharges were not studied. Two of the stud-
ies reported a responder rate based on epileptiform discharges.
For example, Cantello 2007 reported a statistically significant de-
crease in epileptiform discharges by 50% or more from baseline in
one-third of the participants receiving rTMS versus less than 5%
of those receiving sham treatment. Wang 2008 noted there were
significantly fewer participants with epileptiform discharges after
treatment with rTMS (27% of participants) than in the drug-only
group (73% of participants), compared with 100% with such dis-
charges at baseline.
Adverse effects
Seven of 43 participants in Cantello 2007 experienced adverse
effects without a significant difference between active and sham
treatments, with dizziness and headache reported most frequently.
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Sun 2012 had two participants who experienced mild adverse ef-
fects such as headache and tinnitus in the high-intensity group.
Theodore 2002 reported rare adverse effects, with one patient re-
porting mild discomfort and another patient withdrawing after
having a seizure during treatment (but then had 80% decrease
in seizure frequency 2 weeks after treatment). In Joo 2007, five
of 35 participants complained of a mild and transient headache
during and immediately after rTMS. Several participants had a
mild headache and one had insomnia in the Fregni 2006 group,
with no significant difference between the intervention and sham
groups. Five of 15 participants in the rTMS group experienced
headache in the Wang 2008 study compared with none in the
placebo group. Tergau 2003 reported no significant side-effects of
rTMS.
Changes in medication requirements
The proportion of people who required fewer seizure
medications after treatment
None of the studies reported on this outcome.
The proportion of people who required more seizure
medications after treatment
Only one study reported on this outcome. One out of nine partic-
ipants after sham treatment compared with 0 of the active treat-
ment participants required an increase in medication in the Fregni
2006 study.
The proportion of people who had no changes to their
medication after treatment
None of the studies reported on this outcome.
Treatment withdrawal
The proportion of people withdrawn from the study for any
reason
Six of the studies reported on this outcome. Cantello 2007, Fregni
2006, and Joo 2007 reported no withdrawals in any of their partic-
ipants. Sun 2012 had no withdrawals in the high-intensity treat-
ment group, but two out of 29 participants were lost to follow-up
in the low-intensity treatment group. In Theodore 2002, one of
12 active participants developed an unrelated medical condition
(cancer of the colon) and was not included in the eight-week anal-
ysis. Another active participant did not complete the full week of
stimulation due to having had a seizure during stimulation. One
control participant did not keep evaluable seizure calendars for the
post-treatment period and had reported a seizure frequency eight
times the population mean during baseline and was not included
in the analysis. In Tergau 2003, out of 28 patients enrolled, five
are yet to complete the study and six were dropped from analysis
without a reason given. Treatment withdrawal was not reported
by Wang 2008.
The proportion of people withdrawn from the study due to
lack of efficacy or adverse effects
Withdrawals were reported as above and were rare. The only in-
stance when withdrawal was noted to be due to an adverse effect
was in one of 12 active participants in Theodore 2002 after expe-
riencing a seizure during stimulation.
D I S C U S S I O N
Summary of main results
Of the seven studies included in the review, five were completed
and published studies, and included randomized, blinded trials
(Cantello 2007; Fregni 2006; Joo 2007; Sun 2012; Theodore
2002). Two of the studies showed a statistically significant re-
duction in seizure rate from baseline (72% and 78.9% reduction
of seizures per week from the baseline rate, respectively) (Fregni
2006 and Sun 2012). Three randomized, blinded trials showed
no statistically significant difference in seizure frequency follow-
ing rTMS treatment compared with controls (Cantello 2007;
Joo 2007; Theodore 2002). Across studies, seizure frequency and
seizure rates were reported by different measures, time points, and
techniques which precluded comparison between groups.
The other studies reviewed included Wang 2008, which was an
open-label study which showed no significant effect of interven-
tion, and Tergau 2003, an interim analysis. There was a trend to-
wards response reported in Tergau 2003 at two weeks after repeti-
tive transcranial magnetic stimulation (rTMS) with the 0.333 Hz
stimulation subgroup with a 40% reduction in seizure frequency
comparedwith baseline that failed to reach significance when com-
pared with the placebo group. Of the three studies that reported
on the proportion of responders (Cantello 2007; Fregni 2006; Joo
2007), only Fregni 2006 showed a significant high responder rate
of 10 out of 12 active participants experiencing > 50% reduction
in seizure frequency compared with zero responders in the sham
procedure group.
Of the seven studies reviewed, four evaluated our secondary end-
point of change in mean number of epileptic discharges. Fregni
2006, Sun 2012, and Joo 2007 demonstrated a statistically signifi-
cant reduction in epileptiform discharges. In Cantello 2007, there
was no difference in themean reduction in number of epileptiform
discharges, but it did show a statistically significant decrease in
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epileptiform discharges by 50% in more active participants com-
pared with sham. Similarly,Wang 2008 showed significantly fewer
participants with any epileptiform discharges after treatment than
in controls.
Quality of life was not assessed in any of the studies. Adverse ef-
fects were uncommon among the studies and typically involved
headache, dizziness, and tinnitus, with one patient experiencing
a seizure during treatment. Changes in medication requirements
was only reported in one study, which found no significant need
to increase medications in patients after active rTMS. Treatment
withdrawal waswell reported andwas uncommonamong the stud-
ies. Only one patient reportedly withdrew from further rTMS due
to adverse effects and that was because of a seizure.
Overall completeness and applicability of
evidence
Overall, we reviewed seven studies, including230 randomizedpar-
ticipants. One study, Tergau 2003, was only an interim analysis of
a study that was never completed; the rest were completed pub-
lished studies. In most studies, partial/focal epilepsy with or with-
out secondary generalization was more common than diffuse or
multifocal epilepsies. In all studies, participants had drug-resistant
epilepsy, and typically, were either not good surgical candidates or
had declined surgery. Although the inclusion criteria required a
minimum of one to three seizures per week at baseline (depending
on the study) despite medication, the average number of base-
line seizures in the participants were generally greater than 10 per
week in most studies, suggesting these were truly drug-resistant
participants. Thus, the participants studied likely do represent a
clinically relevant population, making the results applicable.
Quality of the evidence
The reviewed studies had a substantial amount of methodological
variability, and details regarding design were not reported in suf-
ficient detail in many studies to make an accurate assessment of
study quality.
The study of Theodore 2002 leaves open the possibility of a mild
treatment effect. A trend towards positive effect was noted, but
the study was only powered to detect a large (70%) reduction in
seizures, making a type II error possible. Their subgroup analysis
showed that focal cortical epilepsies may respond better to rTMS.
Joo 2007 also reported a trend in their focal stimulation, long
duration treatment subgroup with 30.6% reduction (P = 0.059)
from baseline seizure frequency. Their study measured seizure fre-
quency by averaging over eight weeks before and after interven-
tion, and did not report discrete data points, making it difficult to
evaluate whether a potential shorter-lived initial effect was masked
by averaging seizure frequency over such a long period.
Three studies were placebo controlled, where others compared fo-
cal to non-focal application of rTMS or application of rTMS at
different intensities or durations. Even between the placebo con-
trolled studies, differing parameters of frequency (0.3, 0.5, or 1
Hz), intervals, duration (between 500 to 3000 stimuli, daily for
five to seven days in most trials, except Sun 2012 which had 14-
day treatment), and intensity (low of 20% resting motor threshold
(RMT) to high of 120% RMT and one study that used a fixed
high-intensity) were found. We noted that the low-intensity treat-
ment arm in the Sun 2012 study could serve as a de-facto placebo
control group given that the level of stimulation at that intensity
would be unlikely to be effective and indeed did not result in a
statistically significant treatment effect in their study.
Because of this high degree of variability in study design, we were
not able to synthesize results in meta-analysis. We therefore pre-
sented a discussion of the results in narrative text. Overall, we
judged quality of the evidence for the primary outcomes of this
review to be low due to the limited and methodologically unclear
information available. Of the seven studies included, two studies
did show a significant effect, whereas five did not. Given that the
variability of study design and techniques and reported parame-
ters precluded meta-analysis, this narrative review cannot refute
a beneficial effect of rTMS on seizure reduction, though strong
supportive and comparative evidence for efficacy is still lacking.
Potential biases in the review process
Our searches were comprehensive, including searches of un-
published literature and ongoing studies; we hope to include
the identified ongoing study in future updates of the review
(NCT01745952). There is a possibility our searches may have
missed relevant studies, however we believe this to be unlikely.
Given the extent of variability in the design of the included studies,
we felt performing a meta-analysis of study results would be in-
appropriate and that a narrative review, although less informative
and concise than a meta analysis, would provide more reliable and
appropriate interpretations of the results and conclusions drawn
from this review.
Agreements and disagreements with other
studies or reviews
A prior systematic review of 11 studies by Hsu 2011 found a small
but significant effect of low-frequency rTMS on medically in-
tractable epilepsy. However, the effect was based on first measure-
ment after the intervention despite differences in technique and
outcome reporting within each study. The present study found
that no appropriate meta-analysis can be done due to the wide
variability of technique and also time points reported in each
study, as the first measurement could be at one day, two weeks,
or eight weeks after treatment with demonstrable differences in
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effect within individual study parameters. Moreover, the prior sys-
tematic review included additional open-label, non-randomized
studies where all patients received the intervention. The present
review included only randomized studies comparing intervention
and control cohorts.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is evidence that repetitive transcranial magnetic stimulation
(rTMS) is safe and effective at reducing epileptiform discharges
on electroencephalography (EEG). Narrative review of currently
available studies included two studies that showed a significant
effect on seizure frequency and five studies that did not show sig-
nificant effect. Given the variability in technique and outcome re-
porting that prevented meta-analysis, more definitive evidence for
the efficacy of rTMS for seizure reduction in focal drug-resistant
epilepsies is still lacking.
Implications for research
The use of rTMS is still a relatively new therapy for seizures, and
future studies should aim to scientifically establish a standard tech-
nique for its application. There is some evidence that focal epilep-
sies with imaging findings may be more amenable to treatment
with rTMS and further randomized trials are needed to assess its
efficacy for drug-resistant epilepsies. It is important that future tri-
als are of sufficient duration and adequately powered in sample size
to inform longer-term outcomes of efficacy (seizure reduction),
quality of life, and any adverse effects related to rTMS treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cantello 2007
Methods Randomized, double-blind, placebo controlled, cross-over trial
2 treatment arms: 1 placebo first, 1 rTMS first
Pre-randomization baseline period: 12 weeks
Treatment period: twice daily for 5 days in each arm
Follow-up evaluation period: 6 weeks after each treatment or placebo phase for observa-
tion of effect
Total study duration: 14 weeks
Participants A multi-center study in Italy
43 people randomized. 26 participants were male and 17 were female. Mean age 36.9
years (SD 13 years)
All with drug-resistant epilepsy (treated with 2-4 AEDs and experiencing 3 or more
seizures per week), majority were partial epilepsy
Not stated how many participants were randomized to each treatment arm (placebo first
or rTMS first)
Interventions Sham procedure treatment followed by active rTMS or active rTMS followed by sham
treatment
Treatment parameters: two circular coils of 500 stimuli at 0.3 Hz, separated by a 30-
s interval at an intensity of 100% of RMT, placed at the vertex regardless of type of
epilepsy
Outcomes The proportion of people with a 50% or greater reduction in seizure frequency following
the treatment period
Change in seizure frequency per week post-treatment
Mean number of ED seen on EEG during the period between seizures (during and after
the rTMS cycle)
Proportion of people experiencing adverse events and withdrawals from treatment
Notes This trial differs from the others because of its cross-over design (carryover effect is not
formally assessed but the observation period of 6 weeks between treatments is likely to
be a sufficient “washout period”, and that rTMS was placed at the vertex regardless of
type of epilepsy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study used computer-assisted random-
ization to initial active treatment or sham
treatment
Allocation concealment (selection bias) Unclear risk The allocation concealment method was
not specified
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Cantello 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The same apparatus and ’noise’ was used
to blind participants and personnel. Only
the investigator initiating the treatmentwas
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor was blinded to interven-
tion group of participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study attrition was reported, and no miss-
ing data
Selective reporting (reporting bias) Low risk Study protocols not available. Primary and
secondary outcomes stated in methods sec-
tion were reported in results, all expected
outcomes reported
Other bias Unclear risk Observation period of 6 weeks between
treatments is likely to be a sufficient
“washout period” in this cross-over study
Not stated
howmany participants were randomized to
each treatment arm (placebo first or rTMS
first) andwhether these randomized groups
were balanced for clinical demographics at
baseline
Fregni 2006
Methods Randomized, double-blind, sham-controlled parallel design trial
2 treatment arms: active rTMS versus sham rTMS
Baseline observation period: 4 weeks
Follow-up period: 8 weeks
Participants Single-center study in Brazil
21 participants were randomized (12 to active rTMS, 9 to sham rTMS)
All had drug-resistant epilepsy, with a mean frequency of seizures greater than 10 per
month despite 2 or more AEDs, majority had focal epilepsy compared with generalized
epilepsy
Participants either had refused surgery or were poor surgical candidates
12 participants female, 9 male participants. Mean age 21.9 years (SD 8.1 years)
Interventions Treatment period: once a day for 5 consecutive days
Treatment parameters: 1 Hz frequency, fixed intensity of 70% of max stimulator output,
for duration of 20 minutes
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Fregni 2006 (Continued)
Outcomes The proportion of people with a 50% or greater reduction in seizure frequency following
the treatment period
Change in seizure frequency per week post-treatment
Mean number of EDs in the EEG
Proportion of people experiencing adverse events and withdrawals from treatment
Proportion of people who required a change in seizure medication
Notes The design of this study was different from the others due to its use of a fixed intensity
rather than adjusted to resting motor threshold
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomization was performed using the
order of entrance in the study and a ran-
domization table previously generated by
a computer using randomization blocks of
seven (for each seven participants, three
were randomized to sham and four to ac-
tive rTMS) to minimize the risk for unbal-
anced group sizes.” Unclear how the ’or-
der of entrance’ was taken into account in
the randomization and whether this could
have lead to a predictable randomization
sequence
Allocation concealment (selection bias) Unclear risk The allocation concealment method was
not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and study personnel blinded
except for those delivering therapy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor was blinded to interven-
tion group of participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data and study attrition re-
ported
Selective reporting (reporting bias) Low risk Study protocols not available. Primary and
secondary outcomes stated in methods sec-
tion were reported in results, all expected
outcomes reported
Other bias Low risk Appears free of other sources of bias
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Joo 2007
Methods Randomized, double-blind, non-placebo controlled parallel design trial
4 treatment arms: focal rTMS for 3000 pulses (n = 8), focal rTMS for 1500 pulses (n =
10); non-focal rTMS for 3000 pulses (n = 8), and non-focal rTMS for 1500 pulses (n =
9)
Baseline period: 8 weeks
Follow-up period: 8 weeks
Participants Single-center South Korean study
35 subjects with focal, non-focal, or multifocal epilepsy drug-resistant to medications
(range 2-7 AEDs). 18 male participants, 17 female participants
Mean age 25 years (range 18-46 years). Mean seizure frequency 9.1 per week
Interventions Focal (over epileptogenic zone) or non-focal (at vertex) rTMS for 1500 or 3000 pulses
Treatment period: once a day for 5 consecutive days
Treatment parameters: 0.5 Hz frequency, 100% RMT intensity, 50 min duration
Outcomes The proportion of people with a 50% or greater reduction in seizure frequency following
the treatment period
Change in seizure frequency per week post-treatment
Percentage reduction interictal spikes
Proportion of people experiencing adverse events
Notes The design of this study was different from the others due to no placebo control arm;
four active treatment arms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Use of “randomization code” - no further
information reported to assess if the code
was likely to be predictable
Allocation concealment (selection bias) Unclear risk Concealment of allocation not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Only blinding of the EEG reader is speci-
fied. Blinding of participants is not stated,
but they all received active therapy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Only blinding of the EEG reader is speci-
fied, unclear if other outcome assessorswere
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No apparent issues with missing data and
no withdrawals from treatment reported,
but ITT analysis is not specified
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Joo 2007 (Continued)
Selective reporting (reporting bias) High risk Outcomes are not adequately specified in
the methods section (no primary or sec-
ondary outcomes defined)
Other bias Low risk No other sources of bias identified
Sun 2012
Methods Randomized, single-blind, non-placebo controlled parallel design study
Baseline evaluation period: 4 weeks
Follow-up period: 8 weeks
2 treatment arms: high-intensity rTMS at 90% of RMT (n = 31) and low-intensity
rTMS at 20% RMT (n = 29)
Participants 60 participants randomized. Mean age 20.5 years (SD 7 years). 41 male participants, 19
female participants
Various types of epilepsies but majority were partial epilepsy with or without secondary
generalization
20 participants had previously undergone surgical resection which failed to control the
seizures
Interventions Treatment period: 2 weeks
rTMS was delivered 3 times a day for 2 weeks to the focal epileptic zone best reflected
on EEG with 500 stimuli at 0.5 Hz, separated by a 600-s interval
Outcomes Change in seizure frequency per week post-treatment
Proportion of people experiencing adverse events and withdrawals from the study
Effect of rTMS on interical ED at 60 minutes
Notes The design of this study was different from the others due to no placebo control arm;
four active treatment arms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence numbers generated by computer-
assisted randomization program
Allocation concealment (selection bias) Unclear risk Concealment of allocation not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and study personnel blinded
except for those delivering therapy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor was blinded to interven-
tion group of participants
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Sun 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of missing data, and study at-
trition reported. ITT analysis used
Selective reporting (reporting bias) Low risk Study protocols not available. Primary and
secondary outcomes stated in methods sec-
tion were reported in results, all expected
outcomes reported
Other bias Low risk No other sources of bias identified
Tergau 2003
Methods Randomized, placebo and active controlled cross-over trial
3 treatment arms: placebo stimulation first, 0.333 Hz stimulation first, 1 Hz stimulation
first
Baseline period: 3 months
Follow-up period: 4 weeks observation and treatment periods separated by at least 8
weeks
Participants Multi-center study across 3 centers in Germany
Results for 17 randomized participants presented. Mean age 29 years (SD 10 years)
Participants included had any type of medically intractable epilepsy and at least two
seizures per week on average during three month baseline period
Interventions Treatment period: 5 days
Treatment with 1000 pulses each day (500 monopolar pulses with clockwise current
direction followed directly by 500 pulses in anticlockwise direction). Treatment delivered
“unifocally”
Outcomes Change in seizure frequency per week post-treatment
Proportion of people experiencing adverse events and withdrawals from the study
Notes At the time of study publication 28 participants had been enrolled, 5 participants had
yet to complete and six had dropped out of the study (reasons stated). Carryover effect is
not formally assessed but the observation period of at least 8 weeks between treatments
is likely to be a sufficient “washout period”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study is described as randomized, no fur-
ther information given
Allocation concealment (selection bias) Unclear risk Concealment of allocation not described
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Tergau 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk method of placebo stimulation described,
but not stated who was blinded, if anyone
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk method of placebo stimulation described,
but not stated who was blinded, if anyone
Incomplete outcome data (attrition bias)
All outcomes
High risk Data presented for 17 participants out of
28 randomised, ITT approach not used
to analysis. Unclear how many of the
crossover arms were completed by the par-
ticipants who dropped out
Selective reporting (reporting bias) High risk Study protocol not available, Outcomes are
not adequately specified in the methods
section (no primary or secondary outcomes
defined)
Other bias Unclear risk Period of at least 8 weeks between treat-
ments is likely to be a sufficient “washout
period” in this cross-over study
Not stated how many participants were
randomised to each treatment arm (placebo
first, 0.333Hz first or 1Hz first) and
whether these randomised groups were bal-
anced for clinical demographics at baseline.
Unclear how a three arm crossover trial de-
sign was to be implemented (i.e. a second
randomisation after first arm?)
Theodore 2002
Methods Randomized, double-blind, placebo controlled, parallel design trial
2 treatment arms: active rTMS (n = 12) and sham rTMS (n = 12)
Baseline period: 8 weeks
Follow-up period: 8 weeks
Participants Single-center National Institute of Health
24 participants were randomized (13 female, 11 male). Mean age 40 years (SD 14 years)
Participants either had localization related or secondary generalized epilepsy that was
resistant to medications (at least one CPS or secondary GTCS per week on stable AEDs
over 8-week baseline)
Interventions Treatment period: 1 week
Treatment parameters: focal rTMS administered at 1 Hz for 15 minutes twice a day, at
120% RMT
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Theodore 2002 (Continued)
Outcomes Change in seizure frequency per week post-treatment
Proportion of people experiencing adverse events and withdrawals from the study
Notes Authors cited their post-hoc analysis that the study was underpowered to detect less than
a 70% reduction in seizure frequency at 2 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study is described as randomized, no fur-
ther information given
Allocation concealment (selection bias) Unclear risk Concealment of allocation not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and assessment team blinded;
only treatment team unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessment team blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No significant issues with missing data.
Study attrition reported
Selective reporting (reporting bias) Low risk Study protocols not available. Primary out-
come measure described in methods and
reported in results. Secondarymeasures less
clearly stated inmethods, but authorsmake
limited claims based on these secondary re-
sults
Other bias Low risk No additional sources of bias identified
Wang 2008
Methods Randomized, open-label, AED controlled parallel design study
2 treatment arms: TMS plus carbamazepine (n = 15) and “drug treatment” (n = 15)
Baseline period: not stated
Follow-up period: 30 days
Participants Single-center study in China
30 participants randomized (15 to TMS group and 15 to AED group)
TMS group: mean age 27.9 years (SD 4.1 years), 10 males, 5 females. AED group: mean
age 27.6 years (SD 3.9 years), 9 males, 6 females
Participants with temporal lobe epilepsy and epileptiform discharges were enrolled
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Wang 2008 (Continued)
Interventions Treatment period: 7 days (for TMS group), 60 days for AED group
1 Hz TMS at 90% RMT threshold, simulation frequency of 500 times, once a day for
7 days. Drug treatment group received 600-800 mg oral carbamazepine per day for at
least 60 days
Outcomes Change in seizure frequency per week post-treatment
Positive rate of epileptiform charges reported
Proportion of people experiencing adverse events
Notes Imbalance in treatment time across the intervention groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study is described as randomized, no fur-
ther information given
Allocation concealment (selection bias) Unclear risk Concealment of allocation not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open label study (cannot be blinded due
to design), unclear if outcomes were influ-
enced
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label study, outcome assessors not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of missing data, no with-
drawals from the study. ITT analysis used
Selective reporting (reporting bias) Low risk Study protocols not available. Primary and
secondary outcomes stated in methods sec-
tion were reported in results, all expected
outcomes reported
Other bias Low risk No additional sources of bias identified
Abbreviations
AED: antiepileptic drug
CPS: complex partial seizure
ED: epileptiform discharges
EEG: electroencephalogram
GTCS: generalized tonic clonic seizure
Hz: hertz
ITT: intention-to-treat
RMT: resting motor threshold
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rTMS: repetitive transcranial magnetic stimulation
SD: standard deviation
TMS: transcranial magnetic stimulation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
NCT00382707 Before-and-after controlled study
Characteristics of ongoing studies [ordered by study ID]
NCT01745952
Trial name or title Multimodal image-guided repetitive transcranial magnetic stimulation (rTMS) in the treatment of refractory
partial epilepsy
Methods Randomized intervention study, double-blind
Participants Participants with drug-resistant unifocal neocortical epilepsy
Interventions rTMS versus sham rTMS
Outcomes 1) 50% responder rate
2) Percentage of seizure reduction
3) Alteration of brain activation as measured by FDG-PET
4) Difference in seizure reduction using different coil types
5) Quality of life
6) Adverse events
Starting date Nov 2012
Contact information L. Seynaeve, W. Van Paesschen
Notes Authors contacted for more information, no response received
FDG-PET: fluorine-18-fluorodeoxyglucose positron emission tomography
rTMS: repetitive transcranial magnetic stimulation
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Epilepsy Specialized Register search strategy
This was used for the most recent update of the searches.
#1 transcranial magnetic stimulation
#2 >01/06/2014:CRSCREATED AND INREGISTER
#3 #1 AND #2
Appendix 2. CENTRAL via CRSO search strategy
This was used for the most recent update of the searches.
#1 MESH DESCRIPTOR Transcranial Magnetic Stimulation EXPLODE ALL TREES
#2 (“transcranial magnetic stimulation”):TI,AB,KY
#3 #1 OR #2
#4 (epilep* OR seizure* OR convuls*):TI,AB,KY
#5 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES
#6 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#7 #4 OR #5 OR #6
#8 #3 AND #7
#9 * NOT INMEDLINE AND 31/05/2014 TO 29/02/2016:DL
#10 #8 AND #9
Appendix 3. MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011). This was
used for the most recent update of the searches.
1. exp Transcranial Magnetic Stimulation/
2. transcranial magnetic stimulation.tw.
3. 1 or 2
4. exp Epilepsy/
5. exp Seizures/
6. (epilep$ or seizure$ or convuls$).tw.
7. 4 or 5 or 6
8. exp Pre-Eclampsia/ or exp Eclampsia/
9. 7 not 8
10. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
11. clinical trials as topic.sh.
12. trial.ti.
13. 10 or 11 or 12
14. exp animals/ not humans.sh.
15. 13 not 14
16. 3 and 9 and 15
17. remove duplicates from 16
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18. limit 17 to ed=20140601-20160310
Appendix 4. SCOPUS search strategy
(TITLE-ABS-KEY(“Transcranial Magnetic Stimulation”)) and ((TITLE-ABS-KEY(epilep* OR “infantile spasm” OR seizure OR con-
vuls* OR (syndromeW/2 (aicardi OR angelman OR doose OR dravet OR janz OR jeavons OR “landau kleffner” OR “lennox gastaut”
OR ohtahara OR panayiotopoulos OR rasmussen OR rett OR “sturge weber” OR tassinari OR “unverricht lundborg” OR west)) OR
“ring chromosome 20” OR “R20” OR “myoclonic encephalopathy” OR “pyridoxine dependency”) AND NOT (TITLE(*eclampsia)
OR INDEXTERMS(*eclampsia))) OR (TITLE-ABS-KEY(lafora* W/4 (disease OR epilep*)) AND NOT (TITLE(dog OR canine)
OR INDEXTERMS(dog OR canine)))) and (TITLE((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind*
OR “parallel group” OR crossover OR “cross over” OR cluster OR “head to head”) PRE/2 (trial ORmethod OR procedure OR study))
OR ABS((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR “parallel group” OR crossover OR “cross
over” OR cluster OR “head to head”) PRE/2 (trial OR method OR procedure OR study)))
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Addition to ’Types of intervention’ that interventions will be included if ’added to current therapy or used as single therapy.’
Measure of treatment effect for ’quality of life’ specified as mean difference (or standardized mean difference) depending on outcome
scaled used.
Additional information added to ’Unit of analysis’ section to specify methods to be used to analyse cluster-randomized trials and cross-
over trials.
In a post-hoc change from protocol, we have added a ’Summary of findings’ table to the Review (Summary of findings for the main
comparison), reporting the primary outcomes of the review (reduction in seizure frequency and quality of life).
N O T E S
Jennifer Pulman (author of the protocol) is now Jennifer Weston.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Transcranial Magnetic Stimulation [adverse effects]; Drug Resistant Epilepsy [physiopathology; ∗therapy]; Electroencephalography;
Randomized Controlled Trials as Topic
MeSH check words
Humans
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